+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Zykadia

  • PDF Icon

    Report

  • 19 Pages
  • August 2018
  • Region: Global
  • Citeline
  • ID: 4775210
Drug Overview
Zykadia (ceritinib; Novartis) is a tyrosine kinase inhibitor that targets anaplastic lymphoma kinase (ALK). In most ALK-positive non-small cell lung cancer (NSCLC) cases, inversions in chromosome 2 cause ALK to fuse to echinoderm microtubule-associated protein-like 4. This activates the ALK kinase domain and downstream signaling pathways responsible for excess cancer cell proliferation. ALK gene rearrangements are found more commonly in younger, non-smoking NSCLC patients and make up 3–5% of all NSCLC cases.

Table of Contents

OVERVIEW
Drug Overview
Product Profiles
Zykadia : Non-small cell lung cancer (NSCLC)
LIST OF FIGURES
Figure 1: The authors drug assessment summary for Zykadia in non-small cell lung cancer
Figure 101: The authors drug assessment summary for ensartinib in non-small cell lung cancer
Figure 102: The authors drug assessment summary for ensartinib in non-small cell lung cancer
LIST OF TABLES
Table 1: Zykadia drug profile
Table 2: Zykadia pivotal trial data in non-small cell lung cancer
Table 3: Zykadia sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 4: Zykadia patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26